Effects of ghrelin on sexual behavior and luteinizing hormone beta-subunit gene expression in male rats.
Ghrelin is a gut/brain peptide comprising 28 amino acids and is originally identified as the endogenous ligand of the growth hormone secretagogue receptor (GHSR) (1, 2). Ghrelin as a starvation hormone is mainly secreted by the stomach. This peptide is also expressed in the brain, primarily in the hypothalamic arcuate nucleus, an important region for controlling energy balance and reproduction (1, 3). In addition, the presence of ghrelin and its receptors has been reported in GnRH neurons (4) and gonadotrophs of pituitary (5-7). Previous studies have indicated that ghrelin has a direct inhibitory action on GnRH release. Also, ghrelin inhibits luteinizing hormone (LH) release from the pituitary in vivo and in vitro (8-11). The GnRH neurons are the central core of the hypothalamic-pituitary-gonadal (HPG) axis in all vertebrate species; therefore, according to the localization patterns of ghrelin, this peptide has a role in the regulation of HPG axis function (8). Moreover, this peptide has also a suppressive role in the release of testosterone in male mammals (10, 12). On the other hand, ghrelin has been shown to have effects on all three tissues of the HPG axis (10, 12).
Several studies have demonstrated the facilitative effects of hormones secreted from HPG axis on reproductive behavior in male and female animals (13-17). It has been previously shown that GnRH-immunoreactive fibers are present in regions of the brain known to regulate sexual behavior including the bed nucleus of the stria terminalis (BnST), the medial amygdala (mAg) and most notably, the medial preoptic area (mPOA) (18). According to previous studies, administration of gonadotropins and androgens facilitated the sexual behavior in male mammals (13-15). In addition, there are immunohistochemical evidences for the endocrine/paracrine role for ghrelin in the reproductive tissues of mammals (8). These evidences led us to postulate that ghrelin may also reduce sexual activity in addition to inhibiting the HPG axis. To test this hypothesis, the effects of centrally administered ghrelin on sexual behavior in adult male rats were examined. This is the first study for analyzing the effects of ghrelin on all aspects of male sexual behavior in any mammalian species. Moreover, to test whether the locomotion prospects have a role in changes of sexual behavior, another experiment was developed to analyze rats' locomotor activity evaluated by an open field. Alongside the behavioral study, the luteinizing hormone beta-subunit gene expression was assessed following the ghrelin injection. The aim of this assessment was to evaluate the ghrelin's effect on synthesis of LH as one of the indices of HPG axis' activity.
Additionally, an attempt was made to examine whether the possible effects of ghrelin on sexual behavior and LH beta-subunit gene expression depends on an interaction with GHSR-1a (5-7). GHSR-1a is the fully functional type of the ghrelin specific receptors. The broad range of biological processes exerted by ghrelin seem to be mediated by the interaction with specific receptors (57); most of these processes have been abolished by pretreatment with [[D-Lys.sup.3]]-GHRP-6 (DLS), a selective GHS-R1a antagonist (19-22). Hence, DLS was used to determine the role of the GHSR1a, and its antagonistic actions on ghrelin-induced effects.
The aim of present study was to investigate the effects of intracerebroventricular injection of ghrelin, DLS or co-administration of these peptides on sexual behavior and luteinizing hormone beta subunit gene expression in male rats to understand the role of ghrelin as the starvation hormone on attenuation of the sexual behavior indices and LH synthesis in HPG axis.
Animals: One hundred and twenty-eight adult male Wistar rats weighing 200 [+ or -] 20 g were used in this study. The animals were group-housed in polycarbonate cages. Rats were maintained in a temperature controlled room (22 [+ or -] 2[degrees]C) under a 12 hr/ 12 hr light/dark cycle (lights on 08:00). Food and water were available at all times. All procedures for the maintenance and use of experimental animals were pre-approved by the Local Institutional Committee for the Ethical Use of Animals.
Surgery and Injections: All rats were anesthetized by intraperitoneal injection of a mixture of ketamine (80 mg/kg BW) and xylazine (20 mg/kg BW). For central injections, a guide cannula was stereotaxically implanted in the third cerebral ventricle according to the stereotaxic coordinates (AP=-2.3, ML=0.0, DV=6.5) published in the atlas of Paxinos and Watson (1989). The guide cannula consisted of a 22-gauge stainless steel needle secured to the skull with three stainless steel screws and dental cement. One 28-guage stainless steel removable obturator was inserted into the guide cannula to ensure that the cannula remained patent (23). Following the surgery, animals were housed individually. After the eight-day recovery period, these animals were divided into two groups. Each group (n=64) was further subdivided into eight subgroups (n=8 rats/subgroup). Sixty four rats in 8 groups intracerebroventricularly received saline (3 [micro]l), ghrelin (2, 4 or 8 nmol/3 [micro]l), DLS (5 or 10 nmol/3 [micro]l), ghrelin (4 nmol/1.5 [micro]l)+DLS (5 or 10 nmol/1.5 [micro]l) in order to study the sexual behavior, and the other sixty four rats in 8 groups intracere-broventricularly received the same treatments for studying the locomotor activity and gene expression. Doses were chosen based on previous studies, which had established their stimulatory or inhibitory effects on HPG axis or feeding behavior. Ghrelin and DLS (Phoenix Pharmaceutical Inc., CA, USA) were dissolved in saline. Solutions were freshly prepared just before use and were injected by a Hamilton microsyringe (Hamilton Inc., USA). In coadministered group, DLS was injected 5 min before ghrelin injection.
Sexual behavior test: This experiment was conducted in a testing arena (56 x 32 x 32 cm) with a frontal glass. Each naive male rat was individually placed in the arena 10 min after drug administration and allowed to habituate to testing chamber for 5 min; then a sexually active female rat was introduced and the sexual behavior test was performed in 40 min period. The female rats were tested for receptivity before being placed with the males; females that presented lordosis after the mount of a male rat were selected for studying the sexual behavior of naive administrated males. All tests were performed during the late photo phase (15:00-19:00) and the following parameters for each male were recorded: the latencies of first mount (male places its forequarters on hindquarters of female from behind) (ML), first intromission (mount with vaginal insertion) (IL), and first ejaculation (EL); total number of mounts (NM), intromissions (NI) and ejaculations (NE) in 40 min; number of mounts (nM) and intromissions (nl) until the first ejaculation, and post ejaculatory interval (PEI). Additionally, other derived measures were calculated using mentioned parameters including: sum of the NM, NI and NE; copulatory efficiency (CE), and sexual activity index (SAI) based on Agmo et al. (24):
CE = (NI + NE/NM + NI + NE) x 100 SAI = log (1/ML x t) + log (1/IL x t) + log (1/EL x t)V (nM + nI) + Y
The time of the observation was indicated with "t", and "Y" means 4 when an animal ejaculated and 0 when it did not. All latencies were calculated in seconds. The testing arena was cleaned with diluted ethanol after each trial.
Locomotor activity trial: The locomotor activity of administrated rats was evaluated by the open-field test. Ten minutes after injection, all rats were individually placed in a square arena (45 x 45 x 35 cm) divided in to nine equal sectors on the floor. The total number of sectors crossing with all four paws was recorded for 5 min (25).
Gene expression assay: All administrated male rats were decapitated 2 hr after injections; pituitaries were dissected and frozen in liquid nitrogen and stored at -80[degrees]C until processed for reverse transcriptase polymerase chain reaction (RTPCR).
At first, total RNA was extracted using RNX-Plus solution (CinnaGen, Iran). Briefly, pituitaries were separately transferred to 1 ml ice cold RNX-Plus solution and homogenized. Chloroform (200 [micro]l) was added to each sample and after vigorous mixing, centrifuged at 12000 rpm at 4[degrees]C for 15 min; the supernatant was gently mixed with an equal volume of cold isopropanol for 10 min; then the mixture was centrifuged at 12000 rpm at 4[degrees]C for 10 min. The aqueous phase was discarded and the RNA pellet was washed with 1 ml of 75% ethanol. The RNA pellet was quickly dried and reconstituted in 30 [micro]l diethylpyrocarbonate (DEPC) water. The purified total RNA was quantified by the Nano-Drop spectrophotometer (Nano-Drop Technologies, USA).
Then, the synthesis of complementary DNA and the amplification of cDNA templates were carried out using the 2-step RT-PCR Kit (Vivantis Technologies, Malaysia), according to Kit's recommended protocol. For each gene of interest, cDNA template amplification was carried out in a final volume of 25 [micro]l; the mixture consisted of 2.5 [micro]l of synthesized cDNA solution, 1 U of Taq DNA polymerase, 2.5 [micro]l of 10X PCR buffer (10X Vi Buffer A), 0.75 [micro]l of 50 mM Mg[Cl.sub.2], 0.5 [micro]l of 10 mM dNTPs mix, and 0.75 [micro]l of forward and reverse primer mixture. The primers used were as follows: LH[beta] (accession no. NM_012858) forward: AGA GAA TGA GTT CTG CCC AGT CTG, reverse: AGG TCA TTG GTT GAG TCC TGG G (amplicon length 274 bp); and GAPDH  (accession no. BC_013915) forward: AAG AAG GTG GTG AAG CAG GCA TC, reverse: CGA AGG TGG AAG AGT GGG AGT TG (amplicon length 112 bp). The expression levels of LH[beta] were normalized by dividing by GAPDH mRNA expression levels. PCR cycling conditions were as follows: initial denaturation and enzyme activation at 94[degrees]C for 2 min, followed by 35 cycles of denaturation at 94[degrees]C for 30 s, annealing at 59[degrees]C for 30 s (LH[beta]), or 58[degrees]C for 30 s (GAPDH), and extension at 72[degrees]C for 30 s. As a final step, samples were kept at 72[degrees]C for 7 min. After the thermal cycling steps, PCR-amplified products were analyzed by electrophoresis on a 1.5% safe red solution mixed with agarose gel. The molecular size marker, a 100 bp plus, (CinnaGen, Iran) was run concurrently. Finally, gels were visualized under UV illumination and photographed. The intensity of each band was quantified using ImageJ software (version 1.41, USA) and the ratio of LH[beta] to GAPDH was determined.
Statistical analysis: Data are presented as mean [+ or -] SEM. The Kolmogorov-Smirnov test was performed to evaluate the normality of the variables. Multiple comparisons were performed using one-way analysis of variance (ANOVA) followed by Tukey-HSD test by SPSS software (version 19.0, SPSS Inc., USA). Level of p<0.05 was considered statistically significant.
Sexual behavior test: Figure 1 shows the sexual behavior latencies of ghrelin- or DLS-treated male rats. In relation to saline group, 4 or 8 nmol ghrelin significantly increased the mount, intromission and ejaculation latencies. No significant difference was observed between the effects of 5 or 10 nmol DLS and saline group on ML, IL and EL; whereas, a significant difference was observed between the 5 or 10 nmol DLS and 4 nmol ghrelin group. Co-injection of ghrelin (4 nmol) and DLS (5 or 10 nmol) significantly decreased the ML, IL and EL compared to ghrelin (4 nmol) group, but there was no significant difference between the effects of ghrelin (4 nmol)+DLS (5 or 10 nmol) groups and saline group on ML, IL and EL (Figures 1A, 1B, 1C). Different p-values are shown on the figure.
According to figures 2A and 2C, the total number of mount significantly increased and the total number of ejaculation significantly decreased in 40 min following the ghrelin (4 or 8 nmol) injection. No significant difference was observed between the effects of 5 or 10 nmol DLS and saline group on NM and NE; whereas, a significant difference was observed between the 5 or 10 nmol DLS and 4 nmol ghrelin group. Co-administration of ghrelin (4 nmol) and DLS (10 nmol) significantly decreased the NM and significantly increased the NE compared to ghrelin (4 nmol) group, but a significant difference was not observed between the effects of ghrelin (4 nmol)+ DLS (5 nmol) and ghrelin (4 nmol) group on NM and NE (Figures 2A, 2C). According to figure 2B, there were no significant differences among the groups on number of intromission in 40 min. Different p-values were shown on the figure.
Table 1 shows the other parameters of sexual behavior. The post-ejaculatory interval and the parameters related to motor activity (mount and intromission frequencies until the first ejaculation) increased in the ghrelin-received animals compared to control group; co-administration of ghrelin and DLS decreased the mentioned parameters to control range. However, the sum of the total mount, intromission and ejaculation frequencies did not alter under several treatments. The sexual activity index (SAI) and the copulatory efficiency (CE) decreased following the ghrelin injection; DLS pretreatment abolished the inhibitory effect of ghrelin on CE in both 5 and 10 nmol and on SAI at the high dose (10 nmol). Different p-values depended on different doses and are shown in table 1.
Locomotor activity trial: Figure 3 shows the locomotor activity on administrated rats in 5 min. Total number of sectors crossing significantly increased in ghrelin injected rats as compared to control group, while the injection of high dose of DLS (10 nmol) significantly decreased the locomotor activity as compared to saline received rats. Co-administration of ghrelin (4 nmol) and DLS (5 and 10 nmol) significantly decreased locomotion as compared to ghrelin received animals. Different p-values are shown on the figure.
Gene expression assay: Expression of LH[beta] and GAPDH mRNA in the pituitary of male rats is shown in figures 4A and 4B, respectively. The ratio of LH[beta] to GAPDH was determined after the quantification of each band using imageJ software and is shown in figure 4C. Relative LH[beta] mRNA expression significantly (p<0.001) decreased following the ghrelin (4 or 8 nmol) injection, while the administration of DLS (5 or 10 nmol) had no significant effect on gene expression levels. However, co-injection of the lowest effective dose of ghrelin (4 nmol) and the highest non-effective dose of DLS (10 nmol) significantly (p<0.01) increased the relative expression of LH[beta] mRNA compared to ghrelin (4 and 8 nmol) groups.
Identification of ghrelin and its receptors in hypothalamus, pituitary and gonads (3-8) and the subsequent demonstration of the facilitative effects of hormones secreted from these tissues on reproductive behavior (10, 13-16, 18) led us to hypothesize that in addition to affecting on HPG axis, ghrelin may also alter the sexual behavior. This is the first study to analyze the effects of ghrelin and DLS ([[D-Lys.sup.3]]-GHRP-6) on male sexual behavior in any mammalian species. Present results show that ghrelin injection distorted some aspects of sexual behavior and reduced LH[beta] subunit gene expression while enhanced locomotor activity of male rats.
In this study, it was found that ghrelin has simiar inhibitory effects on sexual behavior in male rats as previously reported for female mice in a dose-dependent manner (26). Ghrelin dose dependency increased mount, intromission and ejaculation latencies. These latencies are commonly used for evaluating male sexual motivation (27) characterized by a synchronization of sexual desire arising in the brain and its transmission to the periphery, resulting in penile erection (16, 17). It has been suggested that testosterone positively control both the initiation and the end of the penile erection and that it is a main synchronizer of sexual activity (16, 17). In the absence of testosterone, the sexual desire arising is delayed and uncoordinated with penile erection (16, 17). Previous studies have shown the suppressive role of ghrelin in the release of testosterone in male mammals (10, 12). Ghrelin presumably postponed the beginning of sexual activity through decreasing testosterone in HPG axis. However, this presumption should be investigated. Also, as was observed, pretreatment with DLS reduced the latencies of studied rats.
In this study, despite the decreased number of intromission and ejaculation in ghrelin-received animals, the number of mounts increased in these rats. Nevertheless, there was no difference in sum of the total number of mounts, intromissions and ejaculations among different groups. It suggests that the decrease in the number of intromission and ejaculation after ghrelin injection was compensated by an increase in the number of mounts. In this study, it was demonstrated that ghrelin increased the locomotor activity in the open field test. Presumably, increasing the number of mounts in ghrelin-received animals due to the effects of this peptide on locomotor activity may be a compensatory mechanism to prevent the decreasing of locomotor activity during the intercourse. Previously, a number of studies have been conducted into the effect of ghrelin on locomotion indicating the facilitative effects of this peptide on locomotor activity (28, 29). Nevertheless, there is controversy over the increasing effect of ghrelin on locomotor activity. These discrepancies among studies may be due to the differences in the animal species used, rout or dose of peptide administrated or the photoperiodic condition of experiments (30, 31). Also, few studies showed that DLS treatment or ghrelin receptor deficiency reduced the locomotor activity (29, 32, 33). These findings are compatible with our observations showing that DLS attenuated the enhanced ghrelin-induced locomotor activity and mount frequency. Altogether, it is concluded that the damage in sexual behavior following the ghrelin injection might be the result of other variables rather than locomotion prospects. In other words, this possibility is rejected that reduced sexual behavior after ghrelin injection may result from decreased motor activity.
Considerable decrease in the number of ejaculation as the main factor of success in reproduction process caused a significant decrease in copulatory efficiency in ghrelin-received animals. It may be argued that ghrelin significantly reduced mating success rate. This peptide led to a decrease in the body's ability to perform the ejaculation presumably through the mechanisms regulating energy balance. Nowadays, it is proved that negative energy balance and many food intake-enhancing hormones such as ghrelin have inhibitory effects on the reproductive axis (10, 12, 34, 35). Accordingly, our findings indicating the inhibitory effect
of ghrelin on sexual behavior is compatible with the fact that starvation conditions and negative energy balance prevent the loss of energy in the reproductive pathways. Moreover, ghrelin also increased the interval between the copulatory cycles (PEI), probably due to the delay in the recovery of energy for the next copulation. Calculation of sexual activity index (SAI) in the studied animals confirmed the suppressive effects of ghrelin on reproductive behavior. However, pretreatment with DLS increased the number of ejaculations and in turn improved the mating efficiencies.
The potential implications of these findings are clear; ghrelin has a deleterious effect on male rat's sexual behavior. Up to now, there is no report about the involvement of ghrelin in regulation of the male sexual behavior. However, Bertoldi et al. demonstrated that ghrelin was able to inhibit the sexual behavior of female mice and that it was involved in receptivity reduction after food scarcity (26). Also, Shah and Nyby showed that ghrelin quickly suppressed the androgen-dependent behaviors including the ultrasonic mating calls to a female and the latency to attack a stimulus male through its direct effects on the brain in male house mice, Mus musculus (36). Additionally, in this study DLS, the GHSR-1a antagonist, abolished the prejudicial effects of ghrelin on sexual behavior. The sexual behavior aspects under DLS treatment alone had no significant differences with those in saline-treated rats, while DLS modified the behavioral effects of ghrelin in co-administrated animals. These data suggest that the inhibitory effect of ghrelin on sexual behavior is mediated by GHSR-1a. Previously, DLS has been investigated in food intake (19, 20), inflammatory pain (37), Ischemia-Reperfusion (21), hormone secretion (22) and some other studies in which the several effects of ghrelin were or were not attenuated in animals pretreated with DLS. However, this is the first study evaluating the effects of DLS on male sexual behavior.
It was also revealed that ghrelin and DLS had regulatory effects on LH[beta] subunit gene expression in male rats. In this study, central administration of ghrelin declined the LH[beta] subunit gene expression. Previous neuroanatomical analysis indicated that many ghrelin fibers have been projected to LH contained neurons (6-8) and ghrelin secretion decreased Fos induction in LH neurons and suppressed the LH secretion (8, 10, 11). Therefore, our findings showing the inhibitory effects of ghrelin on LH synthesis are in line with previous studies based on reducing effects of ghrelin on LH release. Notwithstanding the original reports, where ghrelin decreased LH release in several species (8, 10, 11), few studies to date had addressed the suppressive role of ghrelin in LH[beta] subunit gene expression. Moreover, to see whether the effect of ghrelin on LH[beta] expression is mediated through the GHS-R1a or not, DLS was used in this study. Notably, blocking the ghrelin receptor (GHS-R1a) with the antagonist DLS prevented the ghrelin-induced effects on LH[beta] expression. Several lines of evidence suggested the direct and indirect stimulatory effect of luteinizing hormone on regions of the brain which have a role in regulating the male sexual behavior (10, 18, 38). According to these evidences, inhibiting the LH synthesis or release may lead to copulatory deficiency. All in all, our data suggest that ghrelin reduces the LH synthesis and in turn decreases sexual behavior. It is worth mentioning that more studies are required to clarify the direct effects of ghrelin on regions of the brain known to regulate male sexual behavior.
Furthermore, the dose dependent effects of ghrelin were observed on both sexual behavior and locomotor activity in male rats. Therefore, ghrelin in the lowest dose had no significant effect on most of the aspects of sexual behavior while at the same dose, it significantly affected the locomotor activity. It is suggested that the sensitivity of ghrelin receptors in locomotor activity regulating system is more than the ones in the brain regions which control the sexual behavior. Presumably, ghrelin as a starvation hormone in low physiological doses has a negligible effect on mating behavior but continuity of ghrelin release has a remarkable effect on reproductive behavior. Therefore, the negative energy balance that causes the surge of ghrelin may affect reproduction and sexual activities.
In this study, copulatory actions of ghrelin and its specific antagonist, DLS, were examined. To do so, behavioral tests and LH[beta] subunit gene expression assessment were implemented in male rats after injection of different doses of ghrelin or its antagonist through the central rout of administration. Overall, our results suggest that ghrelin in a dose-dependent manner decreased the sexual desire and ability, and postponed the beginning of the intercourse. DLS antagonizes the putative inhibitory role of ghrelin in the regulation of sexual behavior, which involves indirect actions through inhibition of LH synthesis. Additional studies are required about the possible direct effects of ghrelin on brain regions which regulate the male sexual behavior and also about the efficacy of ghrelin following chronic administration.
Conflict of Interest
Authors declare no conflict of interest.
(1.) Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999; 402(6762):656-60.
(2.) Kojima M, Hosoda H, Matsuo H, Kangawa K. Ghrelin: discovery of the natural endogenous ligand for the growth hormone secretagogue receptor. Trends Endocrinol Metab. 2001; 12(3):118-22.
(3.) Lu S, Guan JL, Wang QP, Uehara K, Yamada S, Goto N, et al. Immunocytochemical observation of ghrelin-containing neurons in the rat arcuate nucleus. Neurosci Lett. 2002; 321(3):157-60.
(4.) Cowley MA, Smith RG, Diano S, Tschop M, Pronchuk N, Grove KL, et al. The distribution and mechanism of action of ghrelin in the CNS demonstrates a novel hypothalamic circuit regulating energy homeostasis. Neuron. 2003; 37(4):649-61.
(5.) Guan XM, Yu H, Palyha OC, McKee KK, Feighner SD, Sirinathsinghji DJ, et al. Distribution of mRNA encoding the growth hormone secretagogue receptor in brain and peripheral tissues. Brain Res Mol Brain Res. 1997; 48(1):23-9.
(6.) Howard AD, Feighner SD, Cully DF, Arena JP, Liberator PA, Rosenblum CI, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 1996; 273(5277):974-7.
(7.) McKee KK, Palyha OC, Feighner SD, Hreniuk DL, Tan CP, Phillips MS, et al. Molecular analysis of rat pituitary and hypothalamic growth hormone secretagogue receptors. Mol Endocrinol. 1997; 11(4):41523.
(8.) Miller DW, Harrison JL, Brown YA, Doyle U, Lindsay A, Adam CL, et al. Immunohistochemical evidence for an endocrine/paracrine role for ghrelin in the reproductive tissues of sheep. Reprod Biol Endocrinol. 2005; 3:60.
(9.) Ogata R, Matsuzaki T, Iwasa T, Kiyokawa M, Tanaka N, Kuwahara A, et al. Hypothalamic Ghrelin suppresses pulsatile secretion of luteinizing hormone via beta-endorphin in ovariectomized rats. Neuroendocrinology. 2009; 90(4):364-70.
(10.) Dupont J, Maillard V, Coyral-Castel S, Rame C, Froment P. Ghrelin in female and male reproduction. Int J Pept. 2010; 2010. pii:158102.
(11.) Martini AC, Fernandez-Fernandez R, Tovar S, Navarro VM, Vigo E, Vazquez MJ, et al. Comparative analysis of the effects of ghrelin and unacylated ghrelin on luteinizing hormone secretion in male rats. Endocrinology. 2006; 147(5):2374-82.
(12.) Wang L, Fang F, Li Y, Zhang Y, Pu Y, Zhang X. Role of ghrelin on testosterone secretion and the mRNA expression of androgen receptors in adult rat testis. Syst Biol Reprod Med. 2011; 57(3): 11923.
(13.) Saito TR. Effects of LHRH on copulatory behavior and locomotor activity in sexually inexperienced male rats. Jikken Dobutsu. 1988; 37(4):489-92.
(14.) Awoniyi CA, Reece MS, Hurst BS, Faber KA, Chandrashekar V, Schlaff WD. Maintenance of sexual function with testosterone in the gonadotropin-releasing hormone-immunized hypogonadotropic infertile male rat. Biol Reprod. 1993; 49(6): 1170-6.
(15.) Vignozzi L, Corona G, Petrone L, Filippi S, Morelli AM, Forti G, et al. Testosterone and sexual activity. J Endocrinol Invest. 2005; 28(3 Suppl):39-44.
(16.) Davidson JM. Activation of the male rat's sexual behavior by intracerebral implantation of androgen. Endocrinology. 1966; 79(4):783-94.
(17.) Garelick T, Swann J. Testosterone regulates the density of dendritic spines in the male preoptic area. Horm Behav. 2014; 65(3):249-53.
(18.) Rissman EF. Behavioral regulation of gonadotropin-releasing hormone. Biol Reprod. 1996; 54(2): 413-9.
(19.) Asakawa A, Inui A, Kaga T, Katsuura G, Fujimiya M, Fujino MA, et al. Antagonism of ghrelin receptor reduces food intake and body weight gain in mice. Gut. 2003; 52(7):947-52.
(20.) Beck B, Richy S, Stricker-Krongrad A. Feeding response to ghrelin agonist and antagonist in lean and obese Zucker rats. Life Sci. 2004; 76(4):473-8.
(21.) Brzozowski T, Konturek PC, Sliwowski Z, Pajdo R, Drozdowicz D, Kwiecien S, et al. Prostaglandin/ cyclooxygenase pathway in ghrelin-induced gastroprotection against ischemia-reperfusion injury. J Pharmacol Exp Ther. 2006; 319(1):477-87.
(22.) Unniappan S, Peter RE. In vitro and in vivo effects of ghrelin on luteinizing hormone and growth hormone release in goldfish. Am J Physiol Regul Integr Comp Physiol. 2004; 286(6):R1093-101.
(23.) Lewis MJ, Johnson DF, Waldman D, Leibowitz SF, Hoebel BG. Galanin microinjection in the third ventricle increases voluntary ethanol intake. Alcohol Clin Exp Res. 2004; 28(12):1822-8.
(24.) Agmo A, Paredes R, Fernandez H. Differential effects of GABA transaminase inhibitors on sexual behavior, locomotor activity, and motor execution in the male rat. Pharmacol Biochem Behav. 1987; 28(1):47-52.
(25.) Abilio VC, Vera JA Jr, Ferreira LS, Duarte CR, Martins CR, Torres-Leite D, et al. Effects of melatonin on behavioral dopaminergic supersensitivity. Life Sci. 2003; 72(26):3003-15.
(26.) Bertoldi ML, Luque EM, Carlini VP, Vincenti LM, Stutz G, Santillan ME, et al. Inhibitory effects of ghrelin on sexual behavior: role of the peptide in the receptivity reduction induced by food restriction in mice. Horm Metab Res. 2011; 43(7):494-9.
(27.) Agmo A. Sexual motivation--an inquiry into events determining the occurrence of sexual behavior. Behav Brain Res. 1999; 105(1):129-50.
(28.) Jang JK, Kim WY, Cho BR, Lee JW, Kim JH. Microinjection of ghrelin in the nucleus accumbens core enhances locomotor activity induced by cocaine. Behav Brain Res. 2013; 248:7-11.
(29.) Blum ID, Patterson Z, Khazall R, Lamont EW, Sleeman MW, Horvath TL, et al. Reduced anticipatory locomotor responses to scheduled meals in ghrelin receptor deficient mice. Neuroscience. 2009; 164(2):351-9.
(30.) Yahashi S, Kang KS, Kaiya H, Matsuda K. GHRP6 mimics ghrelin-induced stimulation of food intake and suppression of locomotor activity in goldfish. Peptides. 2012; 34(2):324-8.
(31.) Yannielli PC, Molyneux PC, Harrington ME, Golombek DA. Ghrelin effects on the circadian system of mice. J Neurosci. 2007; 27(11):2890-5.
(32.) Jerlhag E, Engel JA. Ghrelin receptor antagonism attenuates nicotine-induced locomotor stimulation, accumbal dopamine release and conditioned place preference in mice. Drug Alcohol Depend. 2011; 117(2-3): 126-31.
(33.) Maletinska L, Matyskova R, Maixnerova J, Sykora D, Pychova M, Spolcova A, et al. The Peptidic GHS-R antagonist [D-Lys(3)]GHRP-6 markedly improves adiposity and related metabolic abnormalities in a mouse model of postmenopausal obesity. Mol Cell Endocrinol. 2011; 343(1-2):55-62.
(34.) Sakurazawa N, Mano-Otagiri A, Nemoto T, Shibasaki T. Effects of intracerebroventricular ghrelin on food intake and Fos expression in the arcuate nucleus of the hypothalamus in female rats vary with estrous cycle phase. Neurosci Lett. 2013; 541:2048.
(35.) Barreiro ML, Tena-Sempere M. Ghrelin and reproduction: a novel signal linking energy status and fertility? Mol Cell Endocrinol. 2004; 226(1-2):1-9.
(36.) Shah SN, Nyby JG. Ghrelin's quick inhibition of androgen-dependent behaviors of male house mice (Mus musculus). Horm Behav. 2010; 57(3):291-6.
(37.) Sibilia V, Pagani F, Mrak E, Dieci E, Tulipano G, Ferrucci F. Pharmacological characterization of the ghrelin receptor mediating its inhibitory action on inflammatory pain in rats. Amino Acids. 2012; 43 (4): 1751-9.
(38.) Stoyanovitch AG, Johnson MA, Clifton DK, Steiner RA, Fraley GS. Galanin-like peptide rescues reproductive function in the diabetic rat. Diabetes. 2005; 54(8):2471-6.
[1.] Glyceraldehyde-3-phosphate dehydrogenase
Farrin Babaei-Balderlou, Homayoun Khazali *
--Department of Animal Sciences, Faculty of Biological Sciences, Shahid Beheshti University, Tehran, Iran
* Corresponding Author:
Homayoun Khazali, Department of Animal Sciences, Faculty of Biological Sciences, Shahid Beheshti University, Tehran, Iran
Received: Dec. 21, 2014
Accepted: Mar. 8, 2015
Table 1. Sexual behavior parameters of male Wistar rats following ghrelin or [D-[Lys.sup.3]]-GHRP-6 (DLS) injection Ghrelin Saline 2 nmol nM 2.9 [+ or -] 0.5 4.1 [+ or -] 0.5 nI 11.9 [+ or -] 0.9 13.1 [+ or -] 1.1 ([dagger][dagger]) PEI 423.8 [+ or -] 12.2 476.7 [+ or -] 10.7 ([dagger]) NM+NI+NE 34.8 [+ or -] 1.5 33.9 [+ or -] 0.9 SAI 8.5 [+ or -] 0.2 7.7 [+ or -] 0.03 CE 87.4 [+ or -] 2.5 82.9 [+ or -] 2.1 Ghrelin 4 nmol 8 nmol nM 6.7 [+ or -] 0.9 *** 7 [+ or -] 0.7 *** nI 20 [+ or -] 2.2 *** 21.2 [+ or -] 1.7 *** PEI 548 [+ or -] 15.1 *** 562 [+ or -] 10.3 *** NM+NI+NE 33.9 [+ or -] 0.97 34.9 [+ or -] 1.3 SAI 6.8 [+ or -] 0.7 ** 6.6 [+ or -] 0.7 ** CE 77.9 [+ or -] 2.3 77.1 [+ or -] 3.1 * Ghrelin DLS 5 nmol 10 nmol nM 2.2 [+ or -] 0.4 1.9 [+ or -] 0.4 ([dagger][dagger][dagger]) ([dagger][dagger][dagger]) nI 10.4 [+ or -] 0.9 8.8 [+ or -] 0.7 ([dagger][dagger][dagger]) ([dagger][dagger][dagger]) PEI 404.8 [+ or -] 16.2 336.5 [+ or -] 20.6 ** ([dagger][dagger][dagger]) ([dagger][dagger][dagger]) NM+NI+NE 34.4 [+ or -] 1.8 34.6 [+ or -] 1.8 SAI 7.3 [+ or -] 0.1 7.4 [+ or -] 0.1 CE 88.1 [+ or -] 1.6 91.4 [+ or -] 2.3 ([dagger][dagger]) DLS 5 nmol+ DLS 10 nmol+ Ghrelin 4 nmol Ghrelin 4 nmol nM 3.4 [+ or -] 0.4 2.9 [+ or -] 0.6 ([dagger][dagger]) ([dagger][dagger][dagger]) nI 14 [+ or -] 1.2 12 [+ or -] 0.6 ([dagger]) ([dagger][dagger]) PEI 452.1 [+ or -] 12.5 422.1 [+ or -] 13.7 ([dagger][dagger][dagger]) ([dagger][dagger][dagger]) NM+NI+NE 33.4 [+ or -] 1.03 34.6 [+ or -] 1.02 SAI 6.8 [+ or -] 0.1 ** 7.3 [+ or -] 0.03 CE 84.4 [+ or -] 2.2 88.5 [+ or -] 2 ([dagger]) nM = Number of Mounts Until the First Ejaculation; nI = Number of Intromissions Until the First Ejaculation; PEI = Post Ejaculatory Interval; NM+NI+NE = Sum of the Total Number of Mount, Intromission and Ejaculation in 40 min; SAI = Sexual Activity Index; CE=Copulatory Efficiency. Data are represented as mean [+ or -] SEM; * p < 0.05, ** p < 0.01, *** p < 0.001 vs. saline group; ([dagger]) p < 0.05, ([dagger][dagger]) p < 0.01, ([dagger][dagger][dagger]) p < 0.001 vs. ghrelin (4 nmol) group
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Original Article|
|Author:||Babaei-Balderlou, Farrin; Khazali, Homayoun|
|Publication:||Journal of Reproduction and Infertility|
|Date:||Apr 1, 2016|
|Previous Article:||It is time to pay more attention to sperm cryopreservation: now more than ever!|
|Next Article:||The relationship between Chlamydia trachomatis genital infection and spontaneous abortion.|